MammaPrint Predicts Likelihood of pCR With Neoadjuvant Chemo in HR+/HER2– Early Breast Cancer
December 8th 2023Real-world data support the use of the MammaPrint index as a predictor of neoadjuvant chemosensitivity in patients with hormone receptor–positive, HER2-negative early-stage breast cancer.
Read More